Spectral Ai Posts 32% Revenue Drop in Q2
Spectral Ai (NASDAQ:MDAI), a medical technology company specializing in wound care diagnostics, reported its second quarter 2025 results on August 13, 2025. The big news of the release was the completion of its FDA De Novo submission for its DeepView System, an imaging device designed to assess wound healing. However, GAAP revenue of $5.1 million for Q2 2025 fell short of the Wall Street consensus of $5.48 million and reflected a significant year-over-year decrease, with research development revenue (GAAP) declining 32.0% to $5.1 million from $7.5 million. Earnings per share (EPS) on a GAAP basis recorded a deeper loss of $(0.31), compared to $(0.16) in Q2 2024. Overall, the quarter underscored both key strategic progress and ongoing financial headwinds as the company remains mostly dependent on government contracts and awaits regulatory clearance for planned commercial launches.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Spectral Ai develops artificial intelligence-driven diagnostics, with its core product being the DeepView System. This imaging device uses multispectral technology and software to predict wound healing on the first day of injury, targeting hospitals, trauma centers, and burn care units.
Source Fool.com
